Company News

Share this article:

GlaxoSmithKline may owe the IRS nearly $2 billion in back taxes, interest and penalties, the Wall Street Journal reported Friday. The back taxes are a result of “earnings stripping,” a practice multinational companies use to “reduce taxes by claiming interest deductions for payments to a related unit overseas,” the WSJ reported. GSK paid the IRS $3.4 billion in 2006, to end litigation over whether its US operations paid its UK-based parent too much for drugs, which lowered its taxes.

 

Johnson & Johnson announced that it will acquire Cougar Biotechnology for $893 million, or $43 per share. Based in Los Angeles, Cougar Biotech is primarily focused on oncology products, and is currently developing several products for prostate cancer, breast cancer, and other kinds of cancer. Although Cougar doesn't currently have any products on the market, J&J hopes the company's lead candidate, abiraterone acetate (CB7630), now in phase III trials for prostate cancer – will gain an FDA approval by late 2010. Cougar will become part of J&J's Ortho Biotech Oncology Research & Development division.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.